Dataset Information

A synergistically enhanced T(1) -T(2) dual-modal contrast agent.

ABSTRACT: Monodisperse Gd(2) O(3) -embedded iron oxide (GdIO) nanoparticles can simultaneously enhance the local magnetic field intensities of each other under an external magnetic field and result in synergistic enhancement of T(1) and T(2) effects. GdIO nanoparticles have the unique property to be both T(1) and T(2) contrast agents and can potentially lead to higher accuracy in cancer diagnosis, particularly liver tumors.

SUBMITTER: Zhou Z

PROVIDER: S-EPMC3634350 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A synergistically enhanced T(1) -T(2) dual-modal contrast agent.

Zhou Zijian Z Huang Dengtong D Bao Jianfeng J Chen Qiaoli Q Liu Gang G Chen Zhong Z Chen Xiaoyuan X Gao Jinhao J

Advanced materials (Deerfield Beach, Fla.) 20120913 46

Monodisperse Gd(2) O(3) -embedded iron oxide (GdIO) nanoparticles can simultaneously enhance the local magnetic field intensities of each other under an external magnetic field and result in synergistic enhancement of T(1) and T(2) effects. GdIO nanoparticles have the unique property to be both T(1) and T(2) contrast agents and can potentially lead to higher accuracy in cancer diagnosis, particularly liver tumors. ...[more]

PMID: 22972529

Similar Datasets

Project description:Convection-enhanced delivery (CED) is a promising technique for infusing a therapeutic agent directly into the brain, bypassing the blood-brain barrier (BBB) with a pressure gradient to increase drug concentration specifically around the brain tumor, thereby enhancing tumor inhibition and limiting the systemic toxicity of chemotherapeutic agents. Herein, we developed a dual-imaging monitored virus-like nanotherapeutic agent as an ideal CED infusate, which can be delivered to specifically besiege and eradicate brain tumors. Methods: We report one-pot fabrication of green-fluorescence virus-like particles (gVLPs) in Escherichia coli (E. coli) for epirubicin (EPI) loading, cell-penetrating peptide (CPP) modification, and 68Ga-DOTA labeling to form a positron emission tomography (PET)-fluorescence dual-imaging monitored virus-like nanotherapeutic agent (68Ga-DOTA labeled EPI@CPP-gVLPs) combined with CED for brain tumor therapy and image tracking. The drug delivery, cytotoxicity, cell uptake, biodistribution, PET-fluorescence imaging and anti-tumor efficacy of the 68Ga-DOTA labeled EPI@CPP-gVLPs were investigated in vitro and in vivo by using U87-MG glioma cell line and U87-MG tumor model. Results: The 68Ga-DOTA-labeled EPI@CPP-gVLPs showed excellent serum stability as an ideal CED infusate (30-40 nm in size), and can be disassembled through proteolytic degradation of the coat protein shell to enable drug release and clearance to minimize long-term accumulation. The present results indicated that 68Ga-DOTA-labeled EPI@CPP-gVLPs can provide a sufficiently high drug payload (39.2 wt% for EPI) and excellent detectability through fluorescence and PET imaging to accurately represent drug distribution during CED infusion. In vivo delivery of the 68Ga-DOTA-labeled EPI@CPP-gVLPs through CED demonstrated that the median survival was prolonged to over 50 days when the mice received two administrations (once per week) compared with the control group (median survival: 26 days). Conclusion: The results clearly indicated that a combination of 68Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity.

Dataset Information

A synergistically enhanced T(1) -T(2) dual-modal contrast agent.

Publications

A synergistically enhanced T(1) -T(2) dual-modal contrast agent.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets